Publishers
Science & Tech • Business • Investing & Finance
Accelerating Intake: MTMC's Cutting-Edge Approach
January 14, 2025
post photo preview

In the fast-paced world of mass tort litigation, the intake process is a critical component of building a successful case. It is during this initial stage that attorneys gather the information and evidence needed to evaluate the merits of a potential claim and determine the best course of action for their clients. However, the intake process can also be one of the most time-consuming and resource-intensive aspects of mass tort litigation, particularly in cases involving complex medical issues and extensive documentation.

At Mass Tort Medical Consultants (MTMC), founders Keli Heskett and Justine Hanna have recognized the need for a more efficient and effective approach to intake in mass tort cases. Drawing on their backgrounds as legal nurse consultants and their extensive experience in the field, Heskett and Hanna have developed a cutting-edge intake process that leverages technology, medical expertise, and a client-centered approach to accelerate the gathering and analysis of critical information.

One of the key innovations in MTMC's intake process is the use of advanced data management systems and artificial intelligence (AI) tools. These technologies allow MTMC's team to quickly and accurately process large volumes of medical records, identifying key pieces of information and flagging potential issues for further review. By automating many of the routine tasks involved in medical record review, MTMC is able to streamline the intake process and focus their efforts on the most critical aspects of each case.

Another important aspect of MTMC's intake process is the involvement of experienced medical professionals from the outset. Heskett and Hanna have assembled a team of nurses, physicians, and other healthcare experts who work closely with attorneys to evaluate the medical aspects of each case. These experts provide invaluable insights into the strengths and weaknesses of each claim, helping attorneys to make informed decisions about which cases to pursue and how to build the strongest possible arguments.

In addition to their technical expertise, MTMC's medical professionals also play a critical role in building trust and rapport with clients during the intake process. Many individuals who have been harmed by defective products or medical devices are dealing with significant physical, emotional, and financial challenges, and may be hesitant to share sensitive medical information or engage with the legal system. MTMC's team takes a compassionate and patient-centered approach to intake, working closely with clients to understand their unique needs and concerns and to provide the support and guidance they need to feel comfortable moving forward with their claims.

MTMC's intake process also emphasizes the importance of clear and effective communication with clients throughout the process. From the initial contact to the final resolution of each case, MTMC's team works to keep clients informed and engaged, providing regular updates on the status of their claims and answering any questions or concerns they may have. This level of transparency and responsiveness helps to build trust and confidence among clients, and ensures that they feel supported and empowered throughout the legal process.

The benefits of MTMC's cutting-edge intake process are clear. By leveraging technology, medical expertise, and a client-centered approach, MTMC is able to gather and analyze critical information more quickly and accurately than traditional methods, reducing the time and resources required to build strong cases. This efficiency allows attorneys to take on more cases and to pursue claims that might otherwise be too complex or resource-intensive to handle on their own.

Moreover, by involving medical professionals from the outset and prioritizing client communication and support, MTMC is able to build stronger, more compelling cases that are more likely to succeed in court or at the negotiating table. This approach not only benefits individual clients, but also helps to advance the broader goals of mass tort litigation, holding corporations and other entities accountable for the harm they have caused and securing justice for those who have been injured.

If you are an attorney handling mass tort cases and looking for a more efficient and effective approach to intake, partnering with MTMC can provide the expertise, technology, and support you need to accelerate your cases and achieve the best possible outcomes for your clients. Visit www.mtmc1.com to learn more about MTMC's cutting-edge intake process and to explore how their services can benefit your practice.

 

community logo
Join the Publishers Community
To read more articles like this, sign up and join my community today
0
What else you may like…
Posts
Articles
How AI Is Transforming the Waste Management Business for Smarter Routing

The waste management industry is undergoing a dramatic shift thanks to artificial intelligence (AI). From optimizing trash collection routes to predicting maintenance needs for garbage trucks, AI is helping companies reduce operational costs, improve sustainability, and better serve customers. With the rapid advancement of machine learning, computer vision, and IoT (Internet of Things) technologies, AI-driven systems are no longer futuristic—they're being implemented right now in waste operations around the world.

Waste management business leaders are especially benefiting from smarter routing systems made possible by AI. Traditionally, garbage and recycling trucks followed static schedules and routes, often resulting in underfilled bins being collected or full bins being missed. Now, AI-powered systems use real-time data from sensors installed in containers, along with GPS and traffic data, to create the most efficient collection routes possible. These smart-routing algorithms not only reduce ...

post photo preview
Therapist Abuse: Know Your Rights and Why You Need a Lawyer on Your Side

Therapists play a crucial role in supporting mental health and emotional well-being. When working with a therapist, patients entrust them with their most personal experiences and vulnerabilities. Unfortunately, not all therapeutic relationships are safe or ethical. Therapist abuse can cause serious harm, and victims need to understand their rights and legal options. This article will explore what therapist abuse entails, the signs to watch for, and why having a lawyer can make all the difference in seeking justice and protection.
What Is Therapist Abuse?
Therapist abuse refers to any unethical or harmful behavior by a mental health professional toward a patient. Abuse can take many forms, including emotional, physical, sexual, or financial exploitation. Because of the inherent power imbalance in a therapist-patient relationship, abuse can be particularly damaging and complex.
Common Types of Therapist Abuse
Sexual misconduct: This includes any unwanted sexual advances, touching, or inappropriate comments made by a therapist.

Emotional manipulation: Therapists may ...

post photo preview

Video has quickly become one of the most powerful content medium in a business’s marketing toolkit. Whether you’re launching a new product, hosting a live event, or creating brand content, video helps you connect with your audience in ways no other medium can. But there’s a catch: to make great video, you need a great videographer.

And here’s where many new clients go wrong.

Hiring a videographer sounds simple—ask around, check a portfolio, sign a contract, right? Not quite. There are several critical decisions and assumptions that can turn what should be an amazing project into a frustrating (and expensive) disappointment.

In this guide, we’ll cover the top 5 mistakes clients make when hiring a videographer—and how you can avoid them to ensure a smooth, successful, and impactful production.

Mistake #1: Not Defining the Project Goals Clearly

The Problem:
A surprising number of clients approach videographers with vague objectives like “We need a cool video” or “Just make something that looks good.” While the creative freedom might sound appealing, it often leads to misaligned expectations and ...

post photo preview
Biotech Startups Secure Billions for Groundbreaking Autoimmune Therapies Amid Booming Market

In an impressive show of confidence for novel treatment approaches, biotechnology startups focusing on autoimmune diseases have secured massive funding throughout 2025, signaling robust investor enthusiasm for next-generation therapies that could potentially reset immune system function rather than simply managing symptoms. This funding surge comes as the global autoimmune disease therapeutics market demonstrates strong growth projections, with increasing prevalence of conditions like rheumatoid arthritis, lupus, and multiple sclerosis driving unprecedented investment in innovative solutions.

Major Funding Rounds Demonstrate Investor Confidence

The first half of 2025 witnessed remarkable venture capital activity in the autoimmune space, with several startups securing substantial financing to advance their clinical programs. The robust funding environment reflects what industry observers describe as renewed investor confidence for companies with compelling science and clear patient benefits following a market correction in 2022-2023.

Table: Select Autoimmune Therapy Funding Rounds (2024-2025)

Company

Amount Raised

Date

Therapeutic Approach

Primary Indication

Abcuro

$200M

February 2025

Anti-KLRG1 monoclonal antibody

Inclusion body myositis (IBM)

Timberlyne Therapeutics

$180M

January 2025

Anti-CD38 monoclonal antibody

Multiple autoimmune diseases

SetPoint Medical

$140M

August 2025

Vagal nerve modulation device

Rheumatoid arthritis

GlycoEra

$130M

May 2025

IgG4-targeted degrader platform

Multiple autoimmune diseases

Dualitas Therapeutics

$65M

2025

Bispecific antibodies platform

Multiple autoimmune diseases

These financings represent just a portion of the $1.1 billion that autoimmune-focused ventures secured across 17 deals in the first half of 2025 alone, matching the volume and value seen in the previous six-month period. The substantial investments are flowing to companies developing everything from precision extracellular protein degraders to bispecific antibodies and innovative neuroimmunomodulation devices.

Autoimmune Therapeutics Market Demonstrates Strong Growth Trajectory

This startup funding boom occurs against the backdrop of a rapidly expanding global marketplace for autoimmune treatments. The Autoimmune Disease Therapeutics Market was valued at USD 76.33 billion in 2024 and is expected to reach USD 117.33 billion by 2032, growing at a CAGR of 5.52% from 2025-2032. This growth is primarily driven by the rising global prevalence of autoimmune disorders, which have seen incidence increase by 19.1% annually according to National Institutes of Health data. Additional factors fueling market expansion include advancements in biologic therapies, growing R&D investments, and improved diagnostic capabilities enabling earlier treatment intervention.

Strategic Partnerships and M&A Activity Reshape Landscape

Beyond straight equity financing, the autoimmune space has witnessed significant partnership deals and mergers in 2025, demonstrating how established pharmaceutical companies are seeking to supplement their pipelines with innovative external assets.

In the first half of 2025, 21 autoimmune R&D partnerships were completed with a total disclosed value of $10.7 billion – a 34% increase over the previous six-month period despite slightly fewer deals. This boosted the average deal size from $330 million to $510 million, though upfront payments declined significantly, indicating a shift toward back-loaded deal structures with greater reliance on milestone payments.

Notable partnerships included AstraZeneca's discovery-stage deal with Syneron Bio valued at up to $3.4 billion to develop macrocyclic peptide therapies for autoimmune diseases, and Earendil Labs' agreement with Sanofi on a bispecific antibody platform for inflammatory bowel disease, potentially worth $1.7 billion in milestones.

On the mergers and acquisitions front, activity included Alumis's acquisition of Acelyrin in a $737 million all-stock transaction to expand its pipeline in thyroid and neurologic autoimmune conditions, among other strategic combinations.

Novel Therapeutic Approaches Attracting Significant Interest

The diversity of mechanisms receiving funding underscores the breadth of scientific innovation in the autoimmune space. Unlike traditional approaches that broadly suppress the immune system, these novel therapies aim for more precise intervention in disease pathways.

Neuroimmune modulation represents a particularly innovative approach, exemplified by SetPoint Medical's recently funded vagus nerve stimulation technology. "The SetPoint System represents a first-of-its-kind approach to treating rheumatoid arthritis by utilizing neuroimmune modulation," noted company representatives following their $140 million financing round. This technology aims to modulate the body's inflammatory response through targeted electrical stimulation of the vagus nerve, offering a potentially revolutionary non-pharmacological intervention for autoimmune conditions.

Other promising approaches include CAR T-cell therapies for autoimmune conditions, which companies like Bristol Myers Squibb are advancing for lupus and multiple sclerosis , and bispecific antibodies that can simultaneously target multiple disease pathways. Dualitas Therapeutics, which launched with $65 million in Series A funding, is leveraging its DualScreen platform technology to identify promising bispecific combinations for autoimmune treatment.

Market Outlook and Future Directions

The confluence of strong venture funding, strategic partnerships, and market growth projections paints a promising picture for the future of autoimmune disease treatment. The Asia-Pacific region is expected to witness the fastest growth, with a projected CAGR of 7.25% from 2024 to 2032, driven by rising autoimmune disease incidence and improving healthcare access in emerging economies.

As Margaret Keegan, CEO of Precision Medicine Group, observed regarding the evolving biotech funding environment: "A biotech sponsor told me they felt our team cared about their timelines and patient population as much as they did – that's the difference an integrated and genuinely invested partner can make". This shift from transactional relationships to strategic partnerships appears to be paying dividends across the autoimmune therapeutic landscape.

With the global autoimmune disease therapeutics market projected to expand by over $40 billion in the coming years  and venture funding remaining robust for promising science, patients suffering from autoimmune conditions can anticipate a continuing stream of innovative treatments reaching clinical development and eventually the marketplace. The significant investments in novel approaches throughout 2025 suggest the industry is moving beyond traditional immunosuppressive strategies toward more targeted, potentially curative interventions that could dramatically improve patient outcomes in the years ahead.

Read full Article
post photo preview
Biotech Startups Secure Billions for Groundbreaking Autoimmune Therapies Amid Booming Market

In an impressive show of confidence for novel treatment approaches, biotechnology startups focusing on autoimmune diseases have secured massive funding throughout 2025, signaling robust investor enthusiasm for next-generation therapies that could potentially reset immune system function rather than simply managing symptoms. This funding surge comes as the global autoimmune disease therapeutics market demonstrates strong growth projections, with increasing prevalence of conditions like rheumatoid arthritis, lupus, and multiple sclerosis driving unprecedented investment in innovative solutions.

Major Funding Rounds Demonstrate Investor Confidence

The first half of 2025 witnessed remarkable venture capital activity in the autoimmune space, with several startups securing substantial financing to advance their clinical programs. The robust funding environment reflects what industry observers describe as renewed investor confidence for companies with compelling science and clear patient benefits following a market correction in 2022-2023.

Table: Select Autoimmune Therapy Funding Rounds (2024-2025)

Company

Amount Raised

Date

Therapeutic Approach

Primary Indication

Abcuro

$200M

February 2025

Anti-KLRG1 monoclonal antibody

Inclusion body myositis (IBM)

Timberlyne Therapeutics

$180M

January 2025

Anti-CD38 monoclonal antibody

Multiple autoimmune diseases

SetPoint Medical

$140M

August 2025

Vagal nerve modulation device

Rheumatoid arthritis

GlycoEra

$130M

May 2025

IgG4-targeted degrader platform

Multiple autoimmune diseases

Dualitas Therapeutics

$65M

2025

Bispecific antibodies platform

Multiple autoimmune diseases

These financings represent just a portion of the $1.1 billion that autoimmune-focused ventures secured across 17 deals in the first half of 2025 alone, matching the volume and value seen in the previous six-month period. The substantial investments are flowing to companies developing everything from precision extracellular protein degraders to bispecific antibodies and innovative neuroimmunomodulation devices.

Autoimmune Therapeutics Market Demonstrates Strong Growth Trajectory

This startup funding boom occurs against the backdrop of a rapidly expanding global marketplace for autoimmune treatments. The Autoimmune Disease Therapeutics Market was valued at USD 76.33 billion in 2024 and is expected to reach USD 117.33 billion by 2032, growing at a CAGR of 5.52% from 2025-2032. This growth is primarily driven by the rising global prevalence of autoimmune disorders, which have seen incidence increase by 19.1% annually according to National Institutes of Health data. Additional factors fueling market expansion include advancements in biologic therapies, growing R&D investments, and improved diagnostic capabilities enabling earlier treatment intervention.

Strategic Partnerships and M&A Activity Reshape Landscape

Beyond straight equity financing, the autoimmune space has witnessed significant partnership deals and mergers in 2025, demonstrating how established pharmaceutical companies are seeking to supplement their pipelines with innovative external assets.

In the first half of 2025, 21 autoimmune R&D partnerships were completed with a total disclosed value of $10.7 billion – a 34% increase over the previous six-month period despite slightly fewer deals. This boosted the average deal size from $330 million to $510 million, though upfront payments declined significantly, indicating a shift toward back-loaded deal structures with greater reliance on milestone payments.

Notable partnerships included AstraZeneca's discovery-stage deal with Syneron Bio valued at up to $3.4 billion to develop macrocyclic peptide therapies for autoimmune diseases, and Earendil Labs' agreement with Sanofi on a bispecific antibody platform for inflammatory bowel disease, potentially worth $1.7 billion in milestones.

On the mergers and acquisitions front, activity included Alumis's acquisition of Acelyrin in a $737 million all-stock transaction to expand its pipeline in thyroid and neurologic autoimmune conditions, among other strategic combinations.

Novel Therapeutic Approaches Attracting Significant Interest

The diversity of mechanisms receiving funding underscores the breadth of scientific innovation in the autoimmune space. Unlike traditional approaches that broadly suppress the immune system, these novel therapies aim for more precise intervention in disease pathways.

Neuroimmune modulation represents a particularly innovative approach, exemplified by SetPoint Medical's recently funded vagus nerve stimulation technology. "The SetPoint System represents a first-of-its-kind approach to treating rheumatoid arthritis by utilizing neuroimmune modulation," noted company representatives following their $140 million financing round. This technology aims to modulate the body's inflammatory response through targeted electrical stimulation of the vagus nerve, offering a potentially revolutionary non-pharmacological intervention for autoimmune conditions.

Other promising approaches include CAR T-cell therapies for autoimmune conditions, which companies like Bristol Myers Squibb are advancing for lupus and multiple sclerosis , and bispecific antibodies that can simultaneously target multiple disease pathways. Dualitas Therapeutics, which launched with $65 million in Series A funding, is leveraging its DualScreen platform technology to identify promising bispecific combinations for autoimmune treatment.

Market Outlook and Future Directions

The confluence of strong venture funding, strategic partnerships, and market growth projections paints a promising picture for the future of autoimmune disease treatment. The Asia-Pacific region is expected to witness the fastest growth, with a projected CAGR of 7.25% from 2024 to 2032, driven by rising autoimmune disease incidence and improving healthcare access in emerging economies.

As Margaret Keegan, CEO of Precision Medicine Group, observed regarding the evolving biotech funding environment: "A biotech sponsor told me they felt our team cared about their timelines and patient population as much as they did – that's the difference an integrated and genuinely invested partner can make". This shift from transactional relationships to strategic partnerships appears to be paying dividends across the autoimmune therapeutic landscape.

With the global autoimmune disease therapeutics market projected to expand by over $40 billion in the coming years  and venture funding remaining robust for promising science, patients suffering from autoimmune conditions can anticipate a continuing stream of innovative treatments reaching clinical development and eventually the marketplace. The significant investments in novel approaches throughout 2025 suggest the industry is moving beyond traditional immunosuppressive strategies toward more targeted, potentially curative interventions that could dramatically improve patient outcomes in the years ahead.

Read full Article
post photo preview
Daniel J. Cullen: Building Resilient Communities in Wisconsin

Leadership Beyond the Workplace

For Daniel J. Cullen, leadership doesn’t stop at the doors of Precision Metal Fab Inc. While his role as Director requires him to make strategic decisions for long-term business success, he believes his true impact comes from investing in the community around him.

“Strong businesses and strong communities depend on each other,” Cullen explains. “You can’t have one without the other.”

Coaching as Community Building

Through his work as a youth basketball coach in Waukesha and a boxing instructor at both Haley Cullen Wellness and Rock Steady Boxing in Janesville, Cullen uses sports as a way to teach resilience, discipline, and teamwork. These lessons extend beyond athletics, preparing young people and adults alike to contribute positively to society.

Faith and Service as Anchors

Cullen’s commitment to St. Anthony’s on the Lake Family Program reflects his belief that faith and service go hand in hand with civic responsibility. By helping organize family-centered initiatives, he strengthens the bonds that hold communities together.

His participation in the Tim Cullen Institute further highlights his dedication to shaping future civic leaders through mentorship and public engagement.

Resilience Through Responsibility

Cullen believes that resilient communities are built on shared responsibility — from business leaders creating jobs, to coaches mentoring youth, to volunteers supporting families. His own example demonstrates how individuals can strengthen communities by simply showing up and leading with integrity.

Conclusion

For Daniel J. Cullen, building resilient communities means blending professional expertise with personal commitment. By leading in business, coaching in sports, and serving in faith-based and civic programs, he embodies a model of leadership rooted in responsibility.

His story illustrates that resilience isn’t built overnight — it’s created day by day, through service, mentorship, and a commitment to making Wisconsin stronger.

 

Read full Article
Available on mobile and TV devices
google store google store app store app store
google store google store app tv store app tv store amazon store amazon store roku store roku store
Powered by Locals